Brain and Behavior2026Filipa Alves Da Silva, Rita Avelar, Bernardo Peixoto et al.
Depression affects around 280 million people worldwide, and about 30% of patients have treatment-resistant depression. Ketamine has significant scientific evidence supporting its use as an antidepressant, making it a promising approach for treatment-resistant cases. Combining ketamine with psychotherapy may enhance therapeutic response and support longer-lasting cognitive and behavioral change....
PLoS One2026Yijun Wang, Xiaolu Lin, Xiang Zou et al.
Postoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS. This randomized, blinded, controlled trial enrolled single-term pregnant women...
Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-resistant bipolar depression (TRBD) do not respond. This study aimed to identify clinical and sociodemographic characteristics that are associated with nonresponse of anhedonia following short-term ketamine treatment in TRBD. A retrospective analysis...
The non-self (anatta) concept is a distinctive and psychologically vital teaching in Buddhist philosophy. Scholars and psychotherapists working in mindfulness interventions draw on various Buddhist teachings and practices in clinical settings, and many empirical studies demonstrate their effectiveness. This study aimed to investigate the significance of integrating the non-self concept into...
Objective: To investigate neurobiological mechanisms through which esketamine produces rapid antidepressant effects in adolescents with major depressive disorder (MDD), focusing on structural changes in the rostral anterior cingulate cortex (rACC) and associated molecular pathways. Method: A total of 49 adolescents (13-18 years of age) with DSM-5 MDD were randomized to receive intravenous...
Background: Postpartum depression affects 10-20% of new mothers. Non-pharmacological interventions are preferred by breastfeeding mothers, yet evidence for mindfulness-based approaches remains limited. Objective: To evaluate nurse-delivered Mindfulness-Based Stress Reduction on depressive symptoms and stress biomarkers among primiparous mothers with elevated PPD risk. Methods: Single-center...
Ketamines should be used cautiously in bipolar disorder due to its potential to trigger psychosis, and is best reserved for short-term (one-month) treatment of severe depression that might otherwise require hospitalization. While both ECT and TMS are effective for bipolar depression, ECT acts faster and is preferred for more severe cases with psychotic features, with studies showing remission...
Background: Suicidal ideation (SI) represents a clinical challenge in patients with treatment-resistant depression (TRD), and the management of this condition should be as rapid and effective as possible. Intranasal Esketamine has shown promise in patients with TRD due to its rapid onset of action on both SI and depressive symptoms. Since this medication has been recently approved, real-world...
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition...